Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502164 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
A Phase 1 study of Advanced Prostate Adenocarcinoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00502164: Completed Phase 1 study of Advanced Prostate Adenocarcinoma, sponsored by AstraZeneca.
NCT00502164 is a Phase 1 study of Advanced Prostate Adenocarcinoma that has completed, run by AstraZeneca. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00502164, a Phase 1 study of Advanced Prostate Adenocarcinoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
Conditions Studied
Interventions
- DRUG AZD2171
Study Locations (3)
California
- Research Site - San Francisco
Illinois
- Research Site - Chicago
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00502164 record still lists
NCT00502164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Advanced Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which AZD2171 is the first listed.
NCT00502164 reports a single indexed study location in California, Illinois, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00502164 about?
NCT00502164 is a clinical study titled "Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer". A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
What is the current status of trial NCT00502164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-03.
What conditions does trial NCT00502164 study?
This clinical trial studies the following conditions: Advanced Prostate Adenocarcinoma.
What interventions are being tested in trial NCT00502164?
The interventions under investigation include: AZD2171 (DRUG).
Who is sponsoring clinical trial NCT00502164?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00502164 being conducted?
This trial has 3 study locations across California, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00502164's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia